WBB Upgrades Skystar (SKBI) to Sell, Sets $2.50 Price Target
Tweet
Share
E-mailGet Alerts SKBI Hot Sheet
Price: $0.00 --0%
Rating Summary:
0 Buy, 0 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
0 Buy, 0 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
WBB Securities' Stephen Brozak upgraded shares of Skystar Bio-Pharmaceutical Co. (NASDAQ: SKBI) from Short Sell to Sell Thursday morning. The analyst reduced his price target on the stock from $5 to $2.50.
With shares of Skystar down 0.4 percent to $2.76 at last check, Brozak's price target still implies potential downside of about 9 percent.
For an analyst ratings summary and ratings history on Skystar Bio-Pharmaceutical Co. click here. For more ratings news on Skystar Bio-Pharmaceutical Co. click here.
With shares of Skystar down 0.4 percent to $2.76 at last check, Brozak's price target still implies potential downside of about 9 percent.
For an analyst ratings summary and ratings history on Skystar Bio-Pharmaceutical Co. click here. For more ratings news on Skystar Bio-Pharmaceutical Co. click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Similarweb Ltd (SMWB) to Outperform
- Alliance Global Partners Upgrades GrowGeneration (GRWG) to Buy
- Leerink Upgrades Summit Therapeutics plc (SMMT) to Market Perform
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
